{"id":"13dda6d13571","type":"article","url":"https://hartvaat.nl/2026/03/13/nieuwe-acc-aha-richtlijn-dyslipidemie-2026-lagere-ldl-streefwaarden-en-lp-a-meti/","title":"Nieuwe ACC/AHA-richtlijn dyslipidemie 2026: lagere LDL-streefwaarden en Lp(a)-meting aanbevolen","title_en":"2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acc-2026","bempedoïnezuur","dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.11.016","source_url":"https://doi.org/10.1016/j.jacc.2025.11.016","authors":["Blumenthal Roger S","Morris Pamela B","Gaudino Mario","Johnson Heather M","Anderson Timothy S","Bittner Vera A","Blankstein Ron","Brewer LaPrincess C","Cho Leslie","de Ferranti Sarah D","Gianos Eugenia","Gluckman Ty J","Gradney Kristen F","Isiadinso Ijeoma","Lloyd-Jones Donald M","Marrs Joel C","Martin Seth S","McLain Kellie H","Mehta Laxmi S","Mora Samia","Mulugeta Wudeneh M","Natarajan Pradeep","Navar Ann Marie","Orringer Carl E","Polonsky Tamar S","Reynolds Harmony R","Saseen Joseph J","Shapiro Michael D","Soffer Daniel E","Tynes Sheila A","Villavaso Chloé D","Virani Salim S","Wilkins John T"],"significance":10,"published":"2026-03-24","source_date":"2026-03-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"acc-2026","summary_en":"The 2026 ACC/AHA dyslipidemia guideline introduces a universal LDL-cholesterol target of <100 mg/dL for primary prevention and <55 mg/dL for very-high-risk secondary prevention. The guideline endorses earlier initiation of lipid-lowering therapy, Lp(a) measurement, and expanded indications for PCSK9 inhibitors and inclisiran.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T13:31:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De ACC en AHA hebben de richtlijn voor dyslipidemiebehandeling grondig herzien — de eerste update sinds 2018. De belangrijkste veranderingen: een LDL-C-streefwaarde van <100 mg/dL bij intermediair risico en <55 mg/dL bij zeer hoog risico, routinematig meten van lipoproteïne(a), en de inzet van nieuwe therapieën zoals inclisiran en bempedoïnezuur. De richtlijn is hernoemd van 'cholesterol' naar 'dyslipidemie' om de bredere focus op atherogene lipoproteïnen, triglyceriden en Lp(a) te weerspiegelen.","abstract_original":"AIM: The \"2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia\" retires and replaces the \"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.\" METHODS: A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a)."}